Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Halis Akturk to Middle Aged

This is a "connection" page, showing publications Halis Akturk has written about Middle Aged.

 
Connection Strength
  
 
 
0.848
  
  1. Akturk HK, Karakus KE, Chen B, Walker TC. Exploring the Relationship Between Newly Defined Continuous Glucose Monitoring (CGM) Metrics and the Standard CGM Metrics in 30,000 People with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):264-270.
    View in: PubMed
    Score: 0.050
  2. Akturk HK, Karakus KE, Cengiz D, Mason E, Beck E, Kaur G, Garg SK. Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):193-200.
    View in: PubMed
    Score: 0.050
  3. Akturk HK, Mason E, Cengiz D, Karakus KE, Garg SK. Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2026 Jun; 28(6):614-618.
    View in: PubMed
    Score: 0.050
  4. Mason E, Karakus KE, Akturk HK. Barriers to glucagon use in patients with type 1 diabetes. Prim Care Diabetes. 2025 06; 19(3):341-343.
    View in: PubMed
    Score: 0.047
  5. Karakus KE, Snell-Bergeon J, Mason E, Akturk HK. Improvement in Newly Defined Continuous Glucose Monitor Metrics, Extended Hypoglycemia, and Extended Hyperglycemia With Automated Insulin Delivery Initiation in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 May; 20(3):721-726.
    View in: PubMed
    Score: 0.046
  6. Karakus KE, Snell-Bergeon JK, Akturk HK. Comparison of Computational Statistical Packages for the Analysis of Continuous Glucose Monitoring Data with a Reference Software, "Ambulatory Glucose Profile," in Type 1 Diabetes. Diabetes Technol Ther. 2025 03; 27(3):202-208.
    View in: PubMed
    Score: 0.045
  7. Karakus KE, Shah VN, Akturk HK. Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis. JAMA Intern Med. 2024 10 01; 184(10):1246-1247.
    View in: PubMed
    Score: 0.045
  8. Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. 2025 Mar; 19(2):292-296.
    View in: PubMed
    Score: 0.043
  9. Akturk HK, Sakamoto C, Vigers T, Shah VN, Pyle L. Minimum Sampling Duration for Continuous Glucose Monitoring Metrics to Achieve Representative Glycemic Outcomes in Suboptimal Continuous Glucose Monitor Use. J Diabetes Sci Technol. 2025 Mar; 19(2):345-351.
    View in: PubMed
    Score: 0.042
  10. Akturk HK, Snell-Bergeon J, Karakus KE, Shah VN. Assessing the relationship between low-calorie sweetener use and quality of life measures in adults with type 1 diabetes. BMC Endocr Disord. 2023 Jul 11; 23(1):147.
    View in: PubMed
    Score: 0.041
  11. Akturk HK, Couts KL, Baschal EE, Karakus KE, Van Gulick RJ, Turner JA, Pyle L, Robinson WA, Michels AW. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. JAMA Netw Open. 2022 12 01; 5(12):e2246400.
    View in: PubMed
    Score: 0.040
  12. Akturk HK, Brackett S. A Novel and Easy Method to Locate and Remove First Approved Long-Term Implantable Glucose Sensors. Diabetes Technol Ther. 2020 07; 22(7):538-540.
    View in: PubMed
    Score: 0.033
  13. Akturk HK, Alkanani A, Zhao Z, Yu L, Michels AW. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. J Clin Endocrinol Metab. 2018 10 01; 103(10):3589-3592.
    View in: PubMed
    Score: 0.030
  14. Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
    View in: PubMed
    Score: 0.030
  15. Akturk HK, Nippoldt TB. Low Testosterone in Men Should Be a Sign Rather Than a Number to Increase: A Teachable Moment. JAMA Intern Med. 2016 12 01; 176(12):1743-1744.
    View in: PubMed
    Score: 0.026
  16. Akturk HK, Gbadamosi-Akindele M. Elephantiasis nostras verrucosa. BMJ Case Rep. 2014 Mar 28; 2014.
    View in: PubMed
    Score: 0.022
  17. Akturk HK, Vashisht P. How far you can trust c-ANCA? BMJ Case Rep. 2013 Mar 01; 2013.
    View in: PubMed
    Score: 0.020
  18. Karakus KE, Clayton MG, Baschal EE, McDaniel KA, Yu L, Haider Z, Polsky S, Akturk HK, Gottlieb PA, Garg SK, Michels AW. Differences in Clinical Manifestations and Islet Autoantibodies by Age in Adult-Onset Type 1 Diabetes. Diabetes Care. 2026 07 01; 49(7):1194-1201.
    View in: PubMed
    Score: 0.013
  19. Karakus KE, Akturk HK, Kruger D, Ahmann A, Bharvaga A, Langel CR, Ackeifi CA, Rosen J, Pyle L, Snell-Bergeon JK, Shah VN. Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis. Diabetes Care. 2026 May 01; 49(5):718-723.
    View in: PubMed
    Score: 0.013
  20. Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.
    View in: PubMed
    Score: 0.012
  21. Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 06; 27(6):430-438.
    View in: PubMed
    Score: 0.012
  22. Hirsch IB, Beck RW, Marak MC, Kudva Y, Akturk HK, Bhargava A, Codorniz K, Diner J, Aleppo G, Blevins T, Levy CJ, Raskin P, Castorino K, Manessis A, Pickering D, Steenkamp DW, Weinstock RS, Bode BW, Hamdy O, Nguyen QT, Kipnes M, Ruedy KJ, Desjardins D, Haider Z, Jacobson C, Lee S, Buse JB, Klein KR, O'Malley G, Church MM, Mottalib A, Baran JD, Kurek C, Rizvi S, Donahue C, Tamarez D, Atakov Castillo A, Borgman S, Frey S, Calhoun P. A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes. Diabetes Care. 2025 Mar 01; 48(3):353-360.
    View in: PubMed
    Score: 0.012
  23. Beck RW, Bailey RJ, Akturk HK, Rizvi S, Kudva Y, Blevins T, Church MM, Manessis A, Calhoun P, Ruedy KJ, Hirsch IB. A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 03; 27(3):161-169.
    View in: PubMed
    Score: 0.012
  24. Karakus KE, Akturk HK, Snell-Bergeon JK, Shah VN. Progression of Diabetic Retinopathy After Initiation of Automated Insulin Delivery System in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 Jul; 20(4):1159-1163.
    View in: PubMed
    Score: 0.012
  25. Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 01; 27(1):1-9.
    View in: PubMed
    Score: 0.011
  26. Brown SA, Laffel LM, Akturk HK, Forlenza GP, Shah VN, Wadwa RP, Cobry EC, Isganaitis E, Schoelwer M, Lu VS, Rueda R, Sherer N, Corbett JP, Sasson-Katchalski R, Pinsker JE. Randomized, Crossover Trial of Control-IQ Technology with a Lower Treatment Range and a Modified Meal Bolus Module in Adults, Adolescents, Children, and Preschoolers with Varying Levels of Baseline Glycemic Control. Diabetes Technol Ther. 2025 03; 27(3):187-193.
    View in: PubMed
    Score: 0.011
  27. Hirsch IB, Beck RW, Marak MC, Calhoun P, Mottalib A, Salhin A, Manessis A, Coviello AD, Bhargava A, Thorsell A, Atakov Castillo A, Bode BW, Levister C, Levy CJ, Donahue C, Cordero C, Beatson C, Langel CR, Jacobson C, Kurek C, Cruse D, Pickering D, Tamarez D, Steenkamp DW, Desjardins D, Aleppo G, O'Malley G, Akturk HK, Diner J, Baran JD, Buse JB, Ruedy K, Codorniz K, Klein KR, Castorino K, Jordan LF, Kipnes M, Church MM, Hamdy O, Raskin P, Nguyen QT, Weinstock RS, Lee S, Rizvi S, Bzdick S, Ghorbani Rodriguez T, Salah T, Blevins T, Kudva YC, Haider Z. A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery. Diabetes Care. 2024 09 01; 47(9):1682-1687.
    View in: PubMed
    Score: 0.011
  28. Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 06; 26(6):367-374.
    View in: PubMed
    Score: 0.011
  29. Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.
    View in: PubMed
    Score: 0.011
  30. Carlson AL, Graham TE, Akturk HK, Liljenquist DR, Bergenstal RM, Sulik B, Shah VN, Sulik M, Zhao P, Briggs P, Sassan-Katchalski R, Pinsker JE. Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial. J Diabetes Sci Technol. 2024 11; 18(6):1288-1292.
    View in: PubMed
    Score: 0.011
  31. Shah VN, Akturk HK, Trahan A, Piquette N, Wheatcroft A, Schertz E, Carmello K, Mueller L, White K, Fu L, Sassan-Katchalski R, Messer LH, Habif S, Constantin A, Pinsker JE. Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology. J Diabetes Sci Technol. 2024 11; 18(6):1281-1287.
    View in: PubMed
    Score: 0.011
  32. Peter ME, Rioles N, Liu J, Chapman K, Wolf WA, Nguyen H, Basina M, Akturk HK, Ebekozien O, Perez-Nieves M, Poon JL, Mitchell B. Prevalence of fear of hypoglycemia in adults with type 1 diabetes using a newly developed screener and clinician's perspective on its implementation. BMJ Open Diabetes Res Care. 2023 07; 11(4).
    View in: PubMed
    Score: 0.010
  33. Shah VN, Akturk HK, Vigers T, Pyle L, Oliver N, Klonoff DC. Relationship Between Daytime Versus Nighttime Continuous Glucose Monitoring Metrics with A1C in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2023 01; 25(1):62-68.
    View in: PubMed
    Score: 0.010
  34. Kaur H, Schneider N, Pyle L, Campbell K, Akturk HK, Shah VN. Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis. Diabetes Technol Ther. 2019 12; 21(12):736-739.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)